logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Simultaneous administration of adjuvant donor bone marrow in pancreas transplant recipients. Discussion.

    Article, Communication - En anglais

    Annual Scientific Session of the American Surgical Association. San Diego, CA, USA, 1999/04.

    Objective The effect of donor bone marrow was evaluated for its potentially favorable effect in the authors'simultaneous pancreas/kidney transplant program.

    Methods From July 1994 to January 1999,177 pancreas transplants were performed, 151 of which were simultaneous pancreas/kidney transplants.

    All patients received tacrolimus, mycophenolate mofetil, and steroids for immunosuppression (azathioprine was used in the first year of the program).

    Fifty-three simultaneous pancreas/kidney transplant recipients received perioperative unmodified donor bone marrow, 3 to 6 x 108 cells/kg.

    Results Overall actuarial survival rates at 1 and 3 years were 98% and 95% (patient), 95% and 87% (kidney), and 86% and 80% (pancreas), respectively.

    In the adjuvant bone marrow group, 1-and 3-year survival rates were 96% and 91% (patient), 95% and 87% (kidney), and 83% and 83% (pancreas), respectively.

    For 98 recipients who did not receive bone marrow, survival rates at 1 and 3 years were 100% and 98% (patient), 96% and 86% (kidney), and 87% and 79% (pancreas), respectively.

    No pancreas allografts were lost after 3 months in bone marrow recipients, and seven in the non-bone marrow recipients were lost to rejection at 0.7,6.7,8.8,14.6,24.1,24.3, and 25.5 months.

    Twenty-two percent of bone marrow patients were steroid-free at 1 year, 45% at 2 years, and 67% at 3 years.

    Nineteen percent of the non-bone marrow recipients were steroid-free at 1 year, 38% at 2 years, and 45% (p=0.02) at 3 years. (...)

    Mots-clés Pascal : Transplantation, Pancréas, Receveur, Moelle osseuse, Donneur, Traitement adjuvant, Simultané, Evaluation, Efficacité, Etude longitudinale, Homme, Procédure, Chirurgie, Appareil digestif pathologie, Pancréas pathologie

    Mots-clés Pascal anglais : Transplantation, Pancreas, Recipient, Bone marrow, Donor, Adjuvant treatment, Concurrent, Evaluation, Efficiency, Follow up study, Human, Procedure, Surgery, Digestive diseases, Pancreatic disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0516571

    Code Inist : 002B25G03. Création : 18/05/2000.